Keywords: Alzheimer's Disease, Treatment Response, Alzheimer's Disease, blood brain barrier, venous oxygenation
Motivation: Lecanemab treatment in patients with early Alzheimer's disease (AD) may compromise vascular integrity, potentially leading to amyloid-related imaging abnormalities (ARIA), a common side effect associated with anti-amyloid therapies.
Goal(s): To monitor vascular changes in ARIA, including blood-brain barrier (BBB) permeability and cerebral venous oxygenation (Yv), using non-contrast MRI.
Approach: BBB permeability and Yv were compared between PET-confirmed amyloid-positive patients treated with Lecanemab and age-matched untreated controls, as well as across two visits for treated patient.
Results: BBB permeability increased and Yv decreased in the second versus first scan for Lecanemab-treated patients. However, no significant differences were observed between treated and untreated subjects.
Impact: Advanced MRI techniques for assessing BBB permeability and venous oxygenation offer a quantitative approach in detecting early vascular and metabolic changes linked to anti-amyloid treatment, providing valuable insights and tools for monitoring amyloid-related imaging abnormalities (ARIA) and assessing ARIA risk.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords